In Japan, the PMDA is inclined to simply accept CardiAMP scientific information for regulatory submission, permitting BioCardia to organize a Shonin submission, anticipated in about 7 months, with a roughly year-long evaluation post-filing. Within the U.S., FDA recognized the PMA pathway, raised no security issues, and inspired completion of the continued CardiAMP HF II trial.
